Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NIDA-CSP-1021

Division

DTMC

HEAL Study

Investigator(s)

Liza Gorgon, M.A.

Title

Double-Blind, Placebo-Controlled Multi-Center Trial Of Baclofen For The Treatment Of Cocaine Dependence

Short Description

To assess the efficacy and safety of baclofen in reducing cocaine use in subjects with cocaine dependence. It is hypothesized that baclofen treatment, compared to placebo, will be associated with fewer days of cocaine use as assessed by self-report confirmed with urine assays for benzoylecgonine (BE).

Release Date

May 07, 2018

Description

The primary objective of this study is to assess the efficacy of baclofen in reducing cocaine use in subjects with cocaine dependence (DSM-IV criteria). The hypothesis is that baclofen will reduce cocaine use over the treatment period as compared to placebo as determined by selfreport confirmed with urine assays for BE.

Keywords

Assessments

Addiction Severity Index Lite

Brief Substance Craving Scale

Clinical Global Impression Scales

Cocaine Selective Severity Assessment

Hamilton – Depression Rating Scale

HIV Risk-Taking Behaviour Scale